At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CHRO Chromocell Therapeutics Corp.
Closed 12-26 16:00:00 EST
0.6601
+0.0289
+4.58%
盘后0.6986
+0.0385+5.83%
18:47 EST
High0.6740
Low0.6102
Vol28.85K
Open0.6297
D1 Closing0.6312
Amplitude10.11%
Mkt Cap3.98M
Tradable Cap1.05M
Total Shares6.03M
T/O18.43K
T/O Rate1.82%
Tradable Shares1.59M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.